Active Filter(s):
Details:
Nabriva received a Complete Response Letter from the U.S. FDA for the New Drug Application NDA resubmission seeking marketing approval of CONTEPO for injection for the treatment of complicated urinary tract infections (cUTI), including acute pyelonephritis.
Lead Product(s): Fosfomycin Sodium
Therapeutic Area: Infections and Infectious Diseases Product Name: Contepo
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 19, 2020